Baudax Bio Inc expected to post a loss of 77  cents a share - Earnings Preview

Baudax Bio

26/02/2022 03:01

* Baudax Bio Inc  BXRX.OQ   BXRX.O  is expected to show a
rise in
quarterly revenue when it reports  results on February 25
(estimated). 
    * The Malvern Pennsylvania-based  company is expected to
report  a
711.4% increase in revenue to $616.67 thousand from $76 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Baudax Bio Inc is
for a
loss of 77 cents per share. For the same quarter last year, the
company reported a loss of $19.25 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Baudax Bio
Inc is
$70​, about 97.5% above​ its last closing price of $1.77. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -5.47       -5.42      -7.00     Missed  -29
 Jun. 30 2021  -7.49       -7.00      -8.05     Missed  -15
 Mar. 31 2021  -6.59       -6.77      -9.45     Missed  -39.7​
 Dec. 31 2020  -21.14      -21.23     -19.25    Beat    9.3
 ​​Sep.        -29.26      -25.78     21.70     Beat    184.2
 30 2020                                                
 Jun. 30 2020  -25.55      -22.87     -60.20    Missed  -163.3
                                                        ​
 Mar. 31 2020  -61.08      -62.53     -1.35     Missed  -116.6
                                      hundred           
 Dec. 31 2019  -32.78      -32.78     -27.30    Beat    16.7
 This summary was machine generated February 26 at 03:01 GMT. 
All figures in US dollars  unless otherwise stated